Stress-activated mitogen-activated protein kinases c-Jun NH2-terminal kinase and p38 target Cdc25B for degradation. 2009

Sanae Uchida, and Katsuji Yoshioka, and Ryoichi Kizu, and Hitoshi Nakagama, and Tsukasa Matsunaga, and Yukihito Ishizaka, and Randy Y C Poon, and Katsumi Yamashita
Division of Life Science, Graduate School of Natural Science and Technology, Venture Business Laboratory, Center for Innovation, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.

Cdc25 dual specificity phosphatases positively regulate the cell cycle by activating cyclin-dependent kinase/cyclin complexes. Of the three mammalian Cdc25 isoforms, Cdc25A is phosphorylated by genotoxic stress-activated Chk1 or Chk2, which triggers its SCFbeta-TrCP-mediated degradation. However, the roles of Cdc25B and Cdc25C in cell stress checkpoints remain inconclusive. We herein report that c-Jun NH2-terminal kinase (JNK) induces the degradation of Cdc25B. Nongenotoxic stress induced by anisomycin caused rapid degradation of Cdc25B as well as Cdc25A. Cdc25B degradation was dependent mainly on JNK and partially on p38 mitogen-activated protein kinase (p38). Accordingly, cotransfection with JNK1, JNK2, or p38 destabilized Cdc25B. In vitro kinase assays and site-directed mutagenesis experiments revealed that the critical JNK and p38 phosphorylation site in Cdc25B was Ser101. Cdc25B with Ser101 mutated to alanine was refractory to anisomycin-induced degradation, and cells expressing such mutant Cdc25B proteins were able to override the anisomycin-induced G2 arrest. These results highlight the importance of a novel JNK/p38-Cdc25B axis for a nongenotoxic stress-induced cell cycle checkpoint.

UI MeSH Term Description Entries
D010766 Phosphorylation The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety. Phosphorylations
D011499 Protein Processing, Post-Translational Any of various enzymatically catalyzed post-translational modifications of PEPTIDES or PROTEINS in the cell of origin. These modifications include carboxylation; HYDROXYLATION; ACETYLATION; PHOSPHORYLATION; METHYLATION; GLYCOSYLATION; ubiquitination; oxidation; proteolysis; and crosslinking and result in changes in molecular weight and electrophoretic motility. Amino Acid Modification, Post-Translational,Post-Translational Modification,Post-Translational Protein Modification,Posttranslational Modification,Protein Modification, Post-Translational,Amino Acid Modification, Posttranslational,Post-Translational Amino Acid Modification,Post-Translational Modifications,Post-Translational Protein Processing,Posttranslational Amino Acid Modification,Posttranslational Modifications,Posttranslational Protein Processing,Protein Processing, Post Translational,Protein Processing, Posttranslational,Amino Acid Modification, Post Translational,Modification, Post-Translational,Modification, Post-Translational Protein,Modification, Posttranslational,Modifications, Post-Translational,Modifications, Post-Translational Protein,Modifications, Posttranslational,Post Translational Amino Acid Modification,Post Translational Modification,Post Translational Modifications,Post Translational Protein Modification,Post Translational Protein Processing,Post-Translational Protein Modifications,Processing, Post-Translational Protein,Processing, Posttranslational Protein,Protein Modification, Post Translational,Protein Modifications, Post-Translational
D011500 Protein Synthesis Inhibitors Compounds which inhibit the synthesis of proteins. They are usually ANTI-BACTERIAL AGENTS or toxins. Mechanism of the action of inhibition includes the interruption of peptide-chain elongation, the blocking the A site of ribosomes, the misreading of the genetic code or the prevention of the attachment of oligosaccharide side chains to glycoproteins. Protein Synthesis Antagonist,Protein Synthesis Antagonists,Protein Synthesis Inhibitor,Antagonist, Protein Synthesis,Antagonists, Protein Synthesis,Inhibitor, Protein Synthesis,Inhibitors, Protein Synthesis,Synthesis Antagonist, Protein,Synthesis Inhibitor, Protein
D002453 Cell Cycle The complex series of phenomena, occurring between the end of one CELL DIVISION and the end of the next, by which cellular material is duplicated and then divided between two daughter cells. The cell cycle includes INTERPHASE, which includes G0 PHASE; G1 PHASE; S PHASE; and G2 PHASE, and CELL DIVISION PHASE. Cell Division Cycle,Cell Cycles,Cell Division Cycles,Cycle, Cell,Cycle, Cell Division,Cycles, Cell,Cycles, Cell Division,Division Cycle, Cell,Division Cycles, Cell
D002467 Cell Nucleus Within a eukaryotic cell, a membrane-limited body which contains chromosomes and one or more nucleoli (CELL NUCLEOLUS). The nuclear membrane consists of a double unit-type membrane which is perforated by a number of pores; the outermost membrane is continuous with the ENDOPLASMIC RETICULUM. A cell may contain more than one nucleus. (From Singleton & Sainsbury, Dictionary of Microbiology and Molecular Biology, 2d ed) Cell Nuclei,Nuclei, Cell,Nucleus, Cell
D004249 DNA Damage Injuries to DNA that introduce deviations from its normal, intact structure and which may, if left unrepaired, result in a MUTATION or a block of DNA REPLICATION. These deviations may be caused by physical or chemical agents and occur by natural or unnatural, introduced circumstances. They include the introduction of illegitimate bases during replication or by deamination or other modification of bases; the loss of a base from the DNA backbone leaving an abasic site; single-strand breaks; double strand breaks; and intrastrand (PYRIMIDINE DIMERS) or interstrand crosslinking. Damage can often be repaired (DNA REPAIR). If the damage is extensive, it can induce APOPTOSIS. DNA Injury,DNA Lesion,DNA Lesions,Genotoxic Stress,Stress, Genotoxic,Injury, DNA,DNA Injuries
D006367 HeLa Cells The first continuously cultured human malignant CELL LINE, derived from the cervical carcinoma of Henrietta Lacks. These cells are used for, among other things, VIRUS CULTIVATION and PRECLINICAL DRUG EVALUATION assays. Cell, HeLa,Cells, HeLa,HeLa Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006918 Hydroxyurea An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase. Hydroxycarbamid,Hydrea,Oncocarbide
D000841 Anisomycin An antibiotic isolated from various Streptomyces species. It interferes with protein and DNA synthesis by inhibiting peptidyl transferase or the 80S ribosome system. Flagecidin

Related Publications

Sanae Uchida, and Katsuji Yoshioka, and Ryoichi Kizu, and Hitoshi Nakagama, and Tsukasa Matsunaga, and Yukihito Ishizaka, and Randy Y C Poon, and Katsumi Yamashita
August 1998, Circulation research,
Sanae Uchida, and Katsuji Yoshioka, and Ryoichi Kizu, and Hitoshi Nakagama, and Tsukasa Matsunaga, and Yukihito Ishizaka, and Randy Y C Poon, and Katsumi Yamashita
January 2005, Cell biochemistry and biophysics,
Sanae Uchida, and Katsuji Yoshioka, and Ryoichi Kizu, and Hitoshi Nakagama, and Tsukasa Matsunaga, and Yukihito Ishizaka, and Randy Y C Poon, and Katsumi Yamashita
August 1996, Circulation research,
Sanae Uchida, and Katsuji Yoshioka, and Ryoichi Kizu, and Hitoshi Nakagama, and Tsukasa Matsunaga, and Yukihito Ishizaka, and Randy Y C Poon, and Katsumi Yamashita
October 1996, The Journal of infectious diseases,
Sanae Uchida, and Katsuji Yoshioka, and Ryoichi Kizu, and Hitoshi Nakagama, and Tsukasa Matsunaga, and Yukihito Ishizaka, and Randy Y C Poon, and Katsumi Yamashita
March 1998, The Journal of biological chemistry,
Sanae Uchida, and Katsuji Yoshioka, and Ryoichi Kizu, and Hitoshi Nakagama, and Tsukasa Matsunaga, and Yukihito Ishizaka, and Randy Y C Poon, and Katsumi Yamashita
December 1997, The Journal of biological chemistry,
Sanae Uchida, and Katsuji Yoshioka, and Ryoichi Kizu, and Hitoshi Nakagama, and Tsukasa Matsunaga, and Yukihito Ishizaka, and Randy Y C Poon, and Katsumi Yamashita
May 1997, The Journal of biological chemistry,
Sanae Uchida, and Katsuji Yoshioka, and Ryoichi Kizu, and Hitoshi Nakagama, and Tsukasa Matsunaga, and Yukihito Ishizaka, and Randy Y C Poon, and Katsumi Yamashita
June 2001, Zhonghua bing li xue za zhi = Chinese journal of pathology,
Sanae Uchida, and Katsuji Yoshioka, and Ryoichi Kizu, and Hitoshi Nakagama, and Tsukasa Matsunaga, and Yukihito Ishizaka, and Randy Y C Poon, and Katsumi Yamashita
April 1996, The American journal of physiology,
Sanae Uchida, and Katsuji Yoshioka, and Ryoichi Kizu, and Hitoshi Nakagama, and Tsukasa Matsunaga, and Yukihito Ishizaka, and Randy Y C Poon, and Katsumi Yamashita
November 2003, The Journal of biological chemistry,
Copied contents to your clipboard!